WeVote
Log In

Bill

Bill

S 300

An act relating to screening for fentanyl during a hospital-administered urine drug screening

2025-2026 Regular Session Introduced by Steven Heffernan and 1 co-sponsor

Hospitals would include fentanyl screening in hospital-administered urine drug tests to inform clinical decisions and patient safety.

Read 1st time & referred to Committee on Health and Welfare
0
WeVote Research Nonpartisan
Bill Summary · S 300

Bill overview

S.300 (2025-2026 Session, Vermont) is titled: “An act relating to screening for fentanyl during a hospital-administered urine drug screening.” The bill has been read for the first time and referred to the Committee on Health and Welfare. It lists two co-sponsors: Steven Heffernan and Terry Williams.

Purpose and intent

  • The bill aims to require or authorize screening for fentanyl as part of the standard hospital-administered urine drug screening process.
  • The underlying objective is to identify fentanyl presence in patients undergoing urine drug screening within a hospital setting, potentially to inform clinical decision-making, patient safety, and public health data collection.

Key provisions and changes (as articulated by the bill)

  • Mandate/authorize fentanyl screening: The core provision would ensure that fentanyl is screened for in urine samples collected during hospital-administered drug screens. The exact method (e.g., confirmatory testing, point-of-care vs. lab-based, thresholds) and scope (inpatient, emergency department, or all hospital settings) are not specified in the summary provided, but the bill’s title indicates fentanyl screening is a required or standardized component of the hospital screening protocol.
  • Integration with clinical workflows: The bill would likely require hospitals to incorporate fentanyl test results into patient records, with appropriate reporting to clinicians for treatment decisions or safety measures.
  • Data and reporting: There may be implications for how fentanyl screening results are documented, stored, and possibly reported to state health authorities or used for surveillance, though specific reporting requirements are not detailed in the summary.
  • Privacy and consent considerations: The bill would typically address patient privacy and consent related to urine drug screening, consistent with current healthcare privacy laws, though explicit provisions are not described here.
  • Compliance timeline: The summary does not provide a timeline for implementation; if enacted, a date or phased rollout would typically be specified in the bill.

Who would be affected

  • Hospitals and health care facilities in Vermont: They would need to adopt fentanyl screening as part of their urine drug screening protocol.
  • Patients undergoing hospital-administered urine drug screening: They would have fentanyl screening included in their test panels, affecting result reporting and potential clinical actions.
  • Healthcare providers and clinical staff: They would use fentanyl test results to inform treatment decisions, safety protocols, and potential interventions.
  • Health administrators and IT systems: Hospitals may need to modify electronic health records (EHR) and data reporting systems to accommodate screening results and related documentation.

Procedural and timeline aspects

  • Status: Read 1st time and referred to the Committee on Health and Welfare.
  • Next steps: The Committee would review, possibly amend, and vote on the bill. If approved, it would move to the Senate floor for consideration and potentially to the House (depending on Vermont’s bicameral process) before becoming law.
  • Effective date: The summary does not specify an effective date; typical legislation includes an effective date upon enactment or a phased implementation period.

Potential impacts and considerations

  • Public health and safety: Enhanced detection of fentanyl exposure could improve clinical management and risk mitigation for patients and healthcare workers.
  • Resource implications: Hospitals may incur costs related to test kits, laboratory capacity, and IT system updates.
  • Privacy and consent: Patient rights and compliance with privacy laws would need careful alignment with existing medical privacy protections.
  • Equity and access: Implementation should consider rural and under-resourced facilities to ensure consistent access to fentanyl screening.

If you’d like, I can tailor this summary to emphasize potential fiscal impacts, or provide a comparison with existing Vermont screening policies and related statutes.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.